Clinical Trials Logo

Clinical Trial Summary

The clinical trial will investigate the effect of brexpiprazole on the concept of life engagement in patients with MDD with a current depressive episode.


Clinical Trial Description

This is a phase 4, multicenter, open-label, flexible dose trial designed to assess the effects of brexpiprazole (flexible dose; 0.5 to 2 mg QD) as adjunctive therapy to ADT on life engagement in patients with MDD. This trial is being conducted in line with the Canadian Product Monograph. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04830215
Study type Interventional
Source Otsuka Pharmaceutical Development & Commercialization, Inc.
Contact Otsuka Call Center
Phone 844-687-8522
Email [email protected]
Status Recruiting
Phase Phase 4
Start date April 2021
Completion date October 2022

See also
  Status Clinical Trial Phase
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Recruiting NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Suspended NCT02940769 - Neurobiological Effects of Light on MDD Early Phase 1
Not yet recruiting NCT04556890 - Pain and Major Depressive Disorder N/A
Recruiting NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Active, not recruiting NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Active, not recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT04422652 - Combination of Novel Therapies for CKD Comorbid Depression Phase 3
Recruiting NCT04799405 - Home-based tDCS in Major Depressive Disorder N/A
Recruiting NCT03363919 - Biomarkers in Repetitive Transcranial Magnetic Stimulation (rTMS) for Adolescent Depression N/A
Recruiting NCT03708159 - Maintenance of Response After rTMS for Depression Using tDCS N/A
Recruiting NCT04634669 - Open-Label Safety Study of AXS-05 in Subjects With TRD Phase 2
Recruiting NCT03307070 - Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury N/A
Completed NCT03113890 - McLean and Genomind Prospective Study N/A
Recruiting NCT02674529 - Study of Neural Responses Induced by Antidepressant Effects Phase 2/Phase 3
Active, not recruiting NCT02934035 - Early Improvement in Individual Symptoms and Response to Antidepressants in Patients With Major Depressive Disorder N/A
Completed NCT02309060 - Storytelling Video Intervention for Depressed Primary Care Patients - Open Trial N/A
Completed NCT02855580 - Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic
Not yet recruiting NCT02766920 - Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone N/A